The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Editas Medicine, Inc. EDIT announced that it has entered into a collaboration and nonexclusive license agreement with ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary ...

A genome-wide study reveals significant genetic overlap between polycystic ovary syndrome and testosterone-related traits, ...

Drugmakers and insurers are exploring different payment schemes for expensive, potentially curative treatments, particularly ones tied to patient response.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...